Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab

MLA

“Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab.” GlobeNewswire, 12 Sept. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.717060495&authtype=sso&custid=ns315887.

APA

Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab. (2022, September 12). GlobeNewswire.

Chicago

GlobeNewswire. 2022. “Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab,” September 12. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.717060495&authtype=sso&custid=ns315887.